New Agency to Soon Replace French AFSSAPS
France has created a new
The move was announced April 29 in France's Official Journal, which noted the new agency remains under development and the change will be effective in a few months.
MSNA will have a broader regulatory authority for monitoring and evaluation of health products, such as the development of independent research on product safety and requiring clinical studies against active comparators and placebo, Afssaps said in a statement.
The new agency will also have an operating budget greater than Afssaps (157 milliion Euros in 2012 vs. 125 million in 2010) and is financed exclusively by a state subsidy rather than through taxes or user fees from manufacturers.
Afssaps has been reeling from a series of scandals in recent months, including reports that the anti-diabetes drug Mediator was left on the market for a decade longer than was safe and its failure to stop defective breast implants manufactured by Poly Implant Prothese from being implanted into thousands of patients in France.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025